{
    "root": "2f368b45-fe48-646b-e063-6294a90a1b8f",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Risperidone",
    "value": "20250228",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "RISPERIDONE",
            "code": "L6UH7ZF8HC",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_8871"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "ALUMINUM OXIDE",
            "code": "LMI26O6933",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_25741"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "TARTARIC ACID",
            "code": "W4888I119H",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        },
        {
            "name": "BENZOIC ACID",
            "code": "8SKN0B0MIM",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30746"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        },
        {
            "name": "GLYCINE",
            "code": "TE7660XO1C",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15428"
        },
        {
            "name": "CARBOMER HOMOPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED)",
            "code": "4Q93RCW27E",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_60029"
        },
        {
            "name": "ASPARTAME",
            "code": "Z0H242BBR1",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_2877"
        },
        {
            "name": "PEPPERMINT OIL",
            "code": "AV092KU4JH",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11198"
        },
        {
            "name": "XANTHAN GUM",
            "code": "TTV12P4NEE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_189560"
        }
    ],
    "indications": {
        "text": "risperidone atypical antipsychotic indicated : treatment schizophrenia ( 1.1 ) monotherapy adjunctive therapy lithium valproate , treatment acute manic mixed episodes associated bipolar disorder ( 1.2 ) treatment irritability associated autistic disorder ( 1.3 )",
        "doid_entities": [
            {
                "text": "schizophrenia (DOID:5419)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5419"
            },
            {
                "text": "bipolar disorder (DOID:3312)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3312"
            },
            {
                "text": "autistic disorder (DOID:12849)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_12849"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "table 1. recommended daily indication initial dose titration ( increments ) target dose effective dose range schizophrenia : adults ( 2.1 ) 2 mg 1 2 mg 4 8 mg 4 16 mg schizophrenia : adolescents ( 2.2 ) 0.5 mg 0.5 1 mg 3 mg 1 6 mg bipolar mania : adults ( 2.2 ) 2 3 mg 1 mg 1 6 mg 1 6 mg bipolar mania : children adolescents ( 2.2 ) 0.5 mg 0.5 1 mg 1 2.5 mg 1 6 mg irritability autistic disorder ( 2.3 ) 0.25 mg increase 0.5 mg day 4 : ( body weight less 20 kg ) 0.5 mg increase 1 mg day 4 : ( body weight greater equal 20 kg ) day 4 , intervals > 2 weeks : 0.25 mg ( body weight less 20 kg ) 0.5 mg ( body weight greater equal 20 kg ) 0.5 mg : ( body weight less 20 kg ) 1 mg : ( body weight greater equal 20 kg ) 0.5 3 mg severe renal hepatic impairment adults : lower starting dose 0.5 mg twice daily . may increase dosages 1.5 mg twice daily intervals one week longer .",
        "doid_entities": [
            {
                "text": "schizophrenia (DOID:5419)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5419"
            },
            {
                "text": "autistic disorder (DOID:12849)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_12849"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe renal hepatic",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_42738"
            }
        ]
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "risperidone tablets , oral solution , orally disintegrating tablets contraindicated patients known hypersensitivity either risperidone paliperidone , excipients risperidone tablets , oral solution , orally disintegrating tablets formulations . hypersensitivity , including anaphylactic angioedema , reported patients treated risperidone patients treated paliperidone . paliperidone metabolite risperidone .",
    "indications_original": "Risperidone is an atypical antipsychotic indicated for: Treatment of schizophrenia ( 1.1 ) As monotherapy or adjunctive therapy with lithium or valproate, for the treatment of acute manic or mixed episodes associated with Bipolar I Disorder ( 1.2 ) Treatment of irritability associated with autistic disorder ( 1.3 )",
    "contraindications_original": "Table 1. Recommended Daily Dosage by Indication\n                     \n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                           Initial Dose\n                           Titration (Increments)\n                           Target Dose\n                           Effective Dose Range\n                        \n                     \n                     \n                        \n                           \n                              Schizophrenia: adults (\n     \n      2.1)\n    \n     \n                           \n                           2 mg\n                           1 to 2 mg\n                           4 to 8 mg\n                           4 to 16 mg\n                        \n                        \n                           \n                              Schizophrenia: adolescents (\n     \n      2.2)\n    \n     \n                           \n                           0.5 mg\n                           0.5 to 1 mg\n                           3 mg\n                           1 to 6 mg\n                        \n                        \n                           \n                              Bipolar mania: adults (\n     \n      2.2)\n    \n     \n                           \n                           2 to 3 mg\n                           1 mg\n                           1 to 6 mg\n                           1 to 6 mg\n                        \n                        \n                           \n                              Bipolar mania: children and adolescents (\n     \n      2.2)\n    \n     \n                           \n                           0.5 mg\n                           0.5 to 1 mg\n                           1 to 2.5 mg\n                           1 to 6 mg\n                        \n                        \n                           \n                              Irritability in autistic disorder (\n     \n      2.3)\n    \n     \n                           \n                           0.25 mg \n       Can increase to \n       0.5 mg by Day 4: \n       (body weight less than 20 kg) \n     \n                                0.5 mg \n       Can increase to \n       1 mg by Day 4: \n       (body weight greater than or equal to 20 kg)\n    \n                           After Day 4, at intervals of > 2 weeks: \n       0.25 mg \n       (body weight less than 20 kg) \n     \n                                0.5 mg \n       (body weight greater than or equal to 20 kg) \n     \n                           \n                           0.5 mg: \n       (body weight less than 20 kg) \n     \n                                1 mg: \n       (body weight greater than or equal to 20 kg)\n    \n                           0.5 to 3 mg\n                        \n                     \n                  \n                  Severe Renal and Hepatic Impairment in Adults: use a lower starting dose of 0.5 mg twice daily. May increase to dosages above 1.5 mg twice daily at intervals of one week or longer.",
    "adverseReactions_original": "Risperidone Tablets, Oral Solution, or Orally Disintegrating Tablets are contraindicated in patients with a known hypersensitivity to either risperidone or paliperidone, or to any of the excipients in the Risperidone Tablets, Oral Solution, or Orally Disintegrating Tablets formulations. Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone and in patients treated with paliperidone. Paliperidone is a metabolite of risperidone.",
    "drug": [
        {
            "name": "Risperidone",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_8871"
        }
    ]
}